Compared with clopidogrel, the drug comes with better efficacy and less risk of major bleeding than ticagrelor.

While operators from different camps have disparate views and expectations, most agree the time is right for a definitive ...

From November 2024, Ami Bhatt asks Kate Dalton to share details on the challenges of early feasibility studies from her ...

The trend is amplified by an aging population that becomes increasingly vulnerable to CVD tied to rising temperatures.

When pain relief is needed, the agents lessen bleeding risks compared with nonselective NSAIDs, observational data suggest.

The results support the potential to change the trajectory of kidney function decline and extend life expectancy.

May is a busy but invigorating season for the TCTMD team—in-person connections abound and the stream of data never stops. The ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A meta-analysis suggests adverse events are often falsely attributed to BP-lowering drugs, leaving patients undertreated.

Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year ...

A single infusion of a gene-editing therapy called VERVE-102, which targets PCSK9 production in the liver, shows promise for lowering LDL cholesterol in patients with heterozygous familial ...